Drug Profile
FB 704A
Alternative Names: FB-704ALatest Information Update: 23 Aug 2022
Price :
$50
*
At a glance
- Originator Fountain BioPharma
- Developer Oneness Biotech
- Class Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Interleukin 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Asthma
- Phase I Rheumatoid arthritis
- No development reported Cancer
Most Recent Events
- 23 Aug 2022 FB 704A is still in phase I trials for Rheumatoid arthritis in USA (MICROBIO Group pipeline, August 2022)
- 23 Aug 2022 The US FDA approves phase II trial for FB 704A in Asthma in USA, before August 2022 (Oneness Biotech pipeline, August 2022)
- 23 Aug 2022 Oneness Biotech plans a phase II trial for Asthma in USA (IV) (Oneness Biotech pipeline, August 2022)